Andrew Koff

Medicine · Health Sciences

59h-index18.3kcitations248works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(95), Advanced Breast Cancer Therapies(84), Epigenetics and DNA Methylation(34), Microtubule and mitosis dynamics(28), Ubiquitin and proteasome pathways(24)

Publications248 total

Data from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Table 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 1 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Table 2 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure S3 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Figure 4 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Table S5 from Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
2026Open Access
Supplementary Figure from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
2025Open Access
Supplementary Data from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors
2025Open Access
Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma
Cancer Research Communications·2025Open Access
CDK4/6 inhibition induces a DNA damage-independent senescence-associated secretory phenotype driven by delayed activation of NF-κB
2025Open Access
Abstract PS13-04: DREAM complex assembly and stable cell cycle control underlies long-term clinical response to CDK4/6 inhibition
Clinical Cancer Research·2025
page 1 of 13Next →

Frequent Co-authors

Hiroaki Kiyokawa(9), Joan Massagué(6), James M. Roberts(5), Carlos Cordon‐Cardo(5), P Tegtmeyer(5), Kornélia Polyák(4), William D. Tap(4), S. Sean Millard(4), Eduardo Firpo(4), Patrizia Casaccia‐Bonnefil(4), Moses V. Chao(4), Sumitra Deb(4), A L DeLucia(4), Antonio Giordano(3), A DeBlasio(3), Anxo Vidal(3), Mary E. Klein(3), Marta Kovatcheva(3), Mark A. Dickson(3), Aimeé M. Crago(3)